Casma Therapeutics

Executive Summary

Casma Therapeutics is a private biotechnology company focused on developing novel therapies for lysosomal storage disorders and other rare genetic diseases. With $46 million in total funding, the company is advancing preclinical programs leveraging its proprietary platform for enzyme replacement and gene therapy approaches. Although specific pipeline details are undisclosed, Casma's technology aims to address unmet medical needs in pediatric and adult patient populations. The company's progress positions it for potential clinical translation in the near term, contingent on successful regulatory filings and partnership development.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program70% success
• Q4 2026Series B Financing Announcement60% success
• Q2 2026Preclinical Proof-of-Concept Data Publication80% success